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Mutation in Exon 1f of PLEC, Leading
to Disruption of Plectin Isoform 1f, Causes
Autosomal-Recessive Limb-Girdle Muscular Dystrophy
Hulya Gundesli,1 Beril Talim,2 Petek Korkusuz,3 Burcu Balci-Hayta,1 Sebahattin Cirak,4
Nurten A. Akarsu,5 Haluk Topaloglu,6 and Pervin Dincer1,*
Limb-girdle muscular dystrophy (LGMD) is a genetically heterogeneous group of inherited muscular disorders manifesting symmetric,
proximal, and slowly progressive muscle weakness. Using Affymetrix 250K SNPArray genotyping and homozygosity mapping, we map-
ped an autosomal-recessive LGMD phenotype to the telomeric portion of chromosome 8q in a consanguineous Turkish family with
three affected individuals. DNA sequence analysis of PLEC identified a homozygous c.1_9del mutation containing an initiation codon
in exon 1f, which is an isoform-specific sequence of plectin isoform 1f. The same homozygous mutation was also detected in two addi-
tional families during the analysis of 72 independent LGMD2-affected families. Moreover, we showed that the expression of PLEC was
reduced in the patient’s muscle and that there was almost no expression for plectin 1f mRNA as a result of the mutation. In addition to
dystrophic changes inmuscle, ultrastructural alterations, such asmembrane duplications, an enlarged space between themembrane and
sarcomere, and misalignment of Z-disks, were observed by transmission electron microscopy. Unlike the control skeletal muscle, no
sarcolemmal staining of plectin was detected in the patient’s muscle. We conclude that as a result of plectin 1f deficiency, the linkage
between the sarcolemma and sarcomere is broken, which could affect the structural organization of the myofiber. Our data show
that one of the isoforms of plectin plays a key role in skeletal muscle function and that disruption of the plectin 1f can cause the
LGMD2 phenotype without any dermatologic component as was previously reported with mutations in constant exons of PLEC.Limb-girdle muscular dystrophy (LGMD [MIM 253600 and
MIM 159000]) is a clinically well characterized, inherited
form of muscular dystrophies with predominantly prox-
imal or generalized progressive muscle weakness of sym-
metric nature.1,2 Both genders are equally affected, and
the age at onset is usually between 5 and 30 years. Early
motor milestones are usually normal; however, in some
affected individuals, the initial walking age may be de-
layed. LGMDs are known to be genetically heterogeneous,
and both autosomal-dominant (LGMD1) and -recessive
(LGMD2) modes of inheritance are described. Autosomal-
recessive LGMDs are more prevalant (90%) than the auto-
somal-dominant forms (10%) of the disease.3 To date,
mutations in at least 15 genes have been identified as being
responsible for the LGMD2 phenotype.4 These genes and
proteins have variable functions across the muscle fiber,
ranging from structural to enzymatic. The genetic etiology
of many LGMD cases is not yet known, and there are still
quite a number of families that are not linked to any of
the known loci.
We identified a consanguineous Turkish family with four
affected individuals with progressive muscle weakness
(Figure 1A). The index case individual (family 1, patient
VI:1) was a 19-year-old male with delayed independent
walking at 3 years of age. Thereafter, he developed addi-
tional signs of weakness, with occasional falls and difficul-
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his final follow-up (19 years of age) he demonstrated a pro-
longed Gowers sign, with 12 s and generalized muscle
weakness, with proximal muscle strength of 3þ/5 on
the MRC (Medical Research Council) scale (Figure 1B).
He could not jump and walked with increased lumbar
lordosis. Muscle hypertrophy was not observed. There
was no fluctuation of symptoms throughout the day.
Serum creatine kinase (CK) at the age of 19 years was
5584 U/l (n < 191). Echocardiogram showed normal
anatomy and heart function. Pulmonary function tests
did not show any restriction. There were no ocular or
bulbar signs. Intelligence was normal, and the patient
recently graduated from high school. A routine electro-
myogram (EMG) examination was clearly myopathic.
Muscle biopsy showed dystrophic features with variation
in fiber size, internal nuclei, scattered basophilic and few
necrotic fibers, and mild endomysial fibrosis (Figure 1C).
There was a predominance of type 2 fibers, and merosin,
dystrophin, sarcoglycan (alpha, beta, gamma, and delta),
and dystroglycan (alpha and beta) expression was normal
on immunocytochemistry (Figure S1, available online).
There were three additional familymembers with similar
muscle complaints. We examined one uncle, aged 36 years
(family 1, patient V:3), at home (examined by H.T.) one
year ago. This individual was basically bedridden, with
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Figure 1. Clinical and Pathologic Find-
ings
(A) Pedigree of family 1 with LGMD2. DNA
was obtained from individuals III:5, IV:1,
V:2, V.3, V:4, V:5, V:6, V:7, VI:1, VI:2. The
individuals with a horizontal line (V:2,
V:3, V:6, V:7, VI:1) in the pedigree are
studied for homozygosity mapping.
(B) Clinical presentation of patient VI:1
(proband), who has difficulty in raising
from the floor.
(C) Muscle biopsy of patient VI:1 from
family 1, showing prominent variation in
fiber size, few fibers with internal nuclei,
necrotic fibers, and mild increase in endo-
mysial and perimysial connective tissue
(hematoxylin and eosin stain [H&E], orig-
inal magnification 203).
(D) Muscle biopsy of patient 20 from
family 2, at the age of 4 yrs. Variation in
fiber size, fibers with internal nuclei, and
focal increase in endomysial connective
tissue are seen (H&E, original magnifica-
tion 203).contractures, and he had stopped walking at 24 years of
age. He was originally diagnosed with muscular dystrophy
of unknown type at another center, and he declined
further clinical evaluation and expired recently. From
a clinical point of view, two of the patients (family 1,
patients V:3 and VI:1) described herein had early-onset
limb-girdle muscle symptoms followed by years of plateau.
Our index case individual (patient VI:1) was experiencing
progressive muscle weakness, which started to escalate
after 14 years of age. In this specific family, there was one
individual (patient V:1; Figure 1A) with similar muscle
symptoms who died before the diagnosis of the index
case. For genetic work up, DNA samples were obtained
after informed consent was secured from the patients
and relevant family members. The study protocol was
approved by the Hacettepe University Faculty of Medicine
Ethics Commitee (HEK 07/186).
We initially excluded all known LGMD2 loci by linkage
analysis. Genome-wide linkage and homozygosity map-
ping was carried out with the 50K XbaI SNP array (Affyme-
trix). We could not identify a unique homozygous region
in all of the affected individuals despite several approaches,
including parametric linkage analysis (Figure S2). As
shown in the family pedigree (Figure 1A), there are mul-
tiple and distant consanguineous marriages. Thus, mul-
tiple meiosis may result in a very small homozygous region
that may have been missed as a result of the low resolution
of the 50K SNP array. Therefore, we proceeded with Gene-
Chip Mapping 250K NspI SNP arrays from Affymetrix,
which have a higher resolution. Both parents (individuals
V:6 and V:7; Figure 1A) and three affected members of the
pedigree (patients V:2, V:3, and VI:1; Figure 1A) were
included in the analysis. Subsequently, we identified
a single homozygous stretch spanning 3.7 Mb between
SNP marker rs7819473 and the telomere on chromosomeThe American8q24 (Figure 2A).5,6 According to the NCBI Map Viewer
(version 37.1) and the Ensembl database, the common
interval contained approximately 130 known genes.
Among these, plectin (PLEC [MIM 601282]) was a highly
relevant candidate gene, given that it has already been
associated with peculiar forms of muscular dystrophy.7–9
However, mutations in PLEC cause various forms of epider-
molysis bullosa (EB [MIM 131900]), including EB simplex
with muscular dystrophy (EBS-MD [MIM 226670]),7 EB
simplex with pyloric atresia (EBS-PA [MIM 612138]),10,11
and autosomal-dominant inherited EB simplex Ogna (EBS-
OG [MIM 131950]).12 Mutations associated with these
disorders are generally located close to the C-terminal
part of the protein containing the globular domain, which
is a potential binding site for intermediate filaments such
as keratin, desmin, or vimentin.
PLEC is expressed in a wide variety of tissues, including
skin and muscle.13 Because of its widespread distribution
and multiple binding activities, plectin is one of the most
important cytolinkers.14 Moreover, PLEC is a unique gene
because of its unusual 50 transcript diversity.13 It has a
complex organization of 32 exons located on chromosome
8q24.15–18 Although exons 2–32 are constant exons, PLEC
has eight alternative first exons that are spliced into a
common exon 2.16 Additionally, variable first exons of
PLEC are of different lengths and have no sequence simi-
larity that makes the gene unique in the genome. It was
previously reported that there was no conserved motif
upstream of the variable exons and that the positions of
the first exons correspond to the location of CpG islands,
which implies that PLEC has variable multiple promoter
regions.13,16 Analternative promoter region and alternative
cis-splicing of PLEC can explain the tissue- or cell-type-
specific expression, although there is no known mecha-
nism for understanding the cell-tissue specifity of the gene.Journal of Human Genetics 87, 834–841, December 10, 2010 835
Figure 2. Disease Localization and Molecular Analysis
(A) Homozygosity data of the critical region on chromosome 8qtel. Genotype files (CHP) were generated with Affymetrix GTYPE soft-
ware andwere transferred to the VIGENOS (Visual Genome Studio) program (Hemosoft, Ankara), which facilitates visualization of a large
amount of genome data in comprehensible visual screens.5,6 CHR indicates chromosome number. Genetic (cM) and physical (bp) posi-
tion information were obtained from Affymetrix GTYPE. Parents (indicated as V:6 and V:7) and three affected individuals (indicated as
V:2, V:3, and VI:1) from family 1 were included in the analysis. Affected individual VI:1 was chosen as an index case for the construction
of genome-wide haplotypes. Homozygous genotypes identical to the genotype data obtained from the index case are shown in blue.
Contrasting homozygous genotypes are shown in white, whereas heterozygous SNPs appear orange. Noninformativeness due to hetero-
zygous genotypes in parent-child trios is indicated in yellow. Gray indicates no call. The overlapping homozygous stretches of three
affected case individuals are approximately 3.7 Mb and are marked with an arrow in the telomeric part of the chromosome.
(B) Mutation detection by DNA sequence analysis of patient V:3 (homozygous c.1_9del mutation), his mother (heterozygous carrier),
and a control subject. All amplification and sequencing primers used in this study are available in Table S1.
(C) Schematic representation of functional domains of plectin protein and four plectin isoforms (plectins 1, 1b, 1f, and 1d), which have
unique N-terminal sequences. Exon 1f of PLEC (plectin isoform 1f) is mutated, with a 9 bp deletion including the initiation codon
(c.1_9del).As a result of distinct first-exon sequences, a total of
eight plectin isoforms (plectins 1, 1a, 1b, 1c, 1d, 1e, 1f,
and 1g) have been identified with different N termini836 The American Journal of Human Genetics 87, 834–841, Decemband specific functions. Among them, plectin 1a associates
with keratin intermediate filaments in basal keratinocytes,
which supports the association of plectin deficiencies wither 10, 2010
skin disorders.19 Plectins 1, 1b, 1d, and 1f are also substan-
tially expressed inmuscle tissue.20 As already known, PLEC
mutations have been associated with EB simplex with
muscular dystrophy, which is an autosomal-recessive dis-
order characterized by skin blistering and generally late-
onset progressive muscle dystrophy.7 Plectin deficiency
also leads to myasthenic syndrome along with late-onset
myopathy and EBS or congenital muscular dystrophy
with late-onset myasthenic symptoms and EBS, conveying
its substantial role on the neuromuscular junction.8,9
However, no mutation in PLEC has been identified as
being associated with muscular dystrophy without a skin
disorder. In addition to this, no mutation has been
reported in alternative first exons of PLEC corresponding
to plectin isoforms.
DNA sequencing of exons and flanking introns of the
affected individuals (family 1, patients V:2, V:3, and VI:1)
did not detect any mutation in exons 2–32 of plectin-con-
taining functional domains. However, DNA sequencing
of alternative first exons (exons 1, 1b, 1d, and 1f), as well
as part of their 50 UTR and flanking intronic sequences,
revealed homozygous 9 bp deletion (c.1_9del) containing
the initiation codon in exon 1f of the gene (plectin isoform
1f [NM_201378.2]) (Figures 2B and 2C). The parents from
two branches of the family were heterozygous, and healthy
siblings were either heterozygous carriers or completely
normal for this deletion (Figure 1A; individual V:4, normal;
individuals V:5 and VI:2, heterozygous). The mutation was
not detected in 342 alleles of healthy Turkish controls by
DNA sequence analysis.
We extended the analysis to 72 additional LGMD2
patients whose statuses were previously identified as
unlinked to all known LGMD2 loci. The same homozygous
9 bp deletion in exon 1f was identified in two cases from
two different families. One of the patients (family 2,
patient 20) was a 4-yr-old boy of consanguineous parents
with the onset of muscle weakness at 2 yrs. He had
a lordotic gait with a Gowers sign around 4 s. The mental
and fine-motor developmental milestones were normal.
The CK level was 4159 U/l. His 25-yr-old paternal aunt
had muscular dystrophy, proven by a muscle biopsy per-
formed at 23 yrs of age. She was not analyzed by DNA
sequencing for PLEC. The other patient (family 3, patient
47) was a 5-yr-old male child of second cousins with weak-
ness beginning in early childhood. He had walked at
2.5 yrs of age. He always had difficulty climbing stairs
and was behind his peers in running. He initially demon-
strated a Gowers sign around 6 s. Years later, at the age of
13, the duration of the Gowers sign had not changed.
Muscles were not hypertrophic. His serum CK was 3704 U/l.
Both patients showed dystrophic changes in the muscle
biopsy (Figure 1D; patient 20) and normal expression of
merosin, dystrophin, and sarcoglycans (alpha, beta,
gamma, and delta).
Although we did not identify a relationship between
these three families, all of the families originated from
neighboring cities in the Black Sea region of Turkey. Haplo-The Americantype construction using polymorphic DNA markers linked
to the PLEC locus further confirmed a common haplotype
in these families and supported a founder effect (Figure S3).
This mutation was not detected in 342 alleles of healthy
Turkish controls, of which 120 come from the Black Sea
region.
A clinical comparison of patients with exon 1f muta-
tions from three LGMD2 families revealed that they had
early-onset LGMD symptoms followed by years of plateau.
The family history from family 1 may denote a type of
LGMD with loss of ambulation in the late 20s. This indi-
cates that this is a progressive disorder, as our index case
may well be expected to deteriorate in the third to fourth
decades of his life. All case individuals were examined by
a dermatologist, and neither epidermolysis bullosa nor
another dermatologic disorder was reported. The pheno-
type did not show muscle enlargement and was rather
nonspecific as far as the selective muscle involvement in
the clinical setting. None of the patients had myas-
thenic-syndrome-like symptoms such as ocular, facial, or
bulbar involvement, although an involvement of the
neuromuscular junction cannot be ruled out completely,
because single-fiber EMG was not available.
For assessment of the expression of plectin 1f mRNA,
a muscle biopsy was obtained from the right quadriceps
of patient VI:1, and the expression of PLEC was initially
analyzed by semiquantitative RT-PCR (Figure 3A). The rela-
tive densitometric intensity of the bands was measured by
Scion image analysis software (Scion; Frederick, MD, USA).
We detected a 3.2-fold reduction for the expression of
PLEC when patient VI:1’s muscle tissue was compared
with control skeletal muscle tissue. The GAPDH (MIM
138400) level of expression was used for normalization.
We suggest that the decreased expression of PLEC was
due to the plectin 1f deficiency in the patient. Moreover,
the level of expression of plectin 1f mRNAwas determined
by quantitative real-time PCR (qRT-PCR) with the use of
the SYBRGreen JumpStart Taq ReadyMix (S5193) on a Cor-
bett Rotor-Gene 6000 instrument (Corbett Life Science).
In this study, the relative expression of plectin 1f mRNA
in control skeletal muscle and in patient VI:1 was 1 and
0.01, respectively (Figure 3B).21 We found that the defec-
tive plectin isoform 1f exhibited dramatically lower expres-
sion (100-fold) compared to normal skeletal muscle tissue,
which corresponds to a few copies of the plectin 1f mRNA.
These data might be evaluated as an insignificant expres-
sion of plectin 1f mRNA in themuscle tissue of the patient.
In our study, translation will also not occur from the
first ATG as a result of the 9 bp deleted sequence
(ATGGCCGGC) containing a start codon.
In addition to these findings, we decided to determine
the immunolocalization of plectin in skeletal muscle of
patient VI:1 and the control sample. We performed immu-
nofluorescence staining of the muscle tissue (Figures 3C
and 3D). Because there were no commercially available iso-
form-specific plectin antibodies, we used 10F6mAb, which
is against the rod domains of all plectin isoforms. TheJournal of Human Genetics 87, 834–841, December 10, 2010 837
Figure 3. Expression of PLEC and IF Anal-
ysis of Plectin in Patient Muscle
(A) Semiquantitative analysis of PLEC in
skeletal muscle tissue of patient VI:1 and
control muscle. Total RNA was isolated
from the muscle tissue of patient VI:1
and the control via the TRIZOL method.
cDNA synthesis was performed with a
QuantiTect Reverse Transcription Kit
(QIAGEN). It was then amplified by PCR
with primers specific for exons 20 and 23
(20F, 23R) (Table S2). The PCR products
were assessed on a 3% agarose gel. The
amplification product is 338 bp. GAPDH
is an internal control. The amplifica-
tion product of GAPDH is 150 bp. Signifi-
cant reduction of PLEC expression in the
patient’s skeletal muscle is represented.
P-VI:1, patient VI:1 (proband) from family
1; C, control; N, negative control; M, 50 bp
DNA ladder (New England Biolabs).
(B) Analysis of plectin 1f mRNA expression
by qRT-PCR. The exon 1f part of PLEC- and
GAPDH-specific primers (Table S3) were
used for the qRT-PCR reaction, and
the experiments were performed in tripli-
cate. PCR efficiency was 100%. Ct values of both the calibrator (control) and the muscle sample of the patient are normalized to GAPDH
as an internal control. The patient and control samples were analyzed in the same run for the exclusion of between-run variations. A no-
template control of nuclease-free water was included in each run. The experiments were repeated twice for the same samples. The results
were analyzed with Corbett Rotor-Gene 6000 series software, version 1.7. Relative quantitation of gene expression was performed via the
delta-delta CTmethodwith the use of two standard curves.21 The expression level of plectin 1f mRNAwas normalized with the reference
geneGAPDH, and a control sample was used as a calibrator. Data represent a 100-fold decreased expression of plectin 1f mRNA in patient
VI:1’s (P-VI:1) skeletal muscle with respect to the control sample.
(C and D) Immunofluorescence analysis of plectin in control muscle and patient VI:1 (P-VI:1), respectively. Cross sections of the muscle
tissues were stained with plectin 10F6 (mAb) antibody. Strong sarcoplasmic staining, but no sarcolemmal staining, was detected in the
patient muscle when compared to the control sample. Arrows show the sarcolemmal staining of type 2 fibers (fibers with sarcoplasmic
staining) and type 1 fibers in control skeletal muscle. Scale bars represent 50 mm.plectin 10F6 antibody was a gift from Dr. Gerhard Wiche
(University of Vienna).
It was previously proposed that plectin 1f is a sarco-
lemma-associated protein, and it could be localized
beneath the sarcolemma. With pan-plectin antiserum,
strong subsarcolemmal and moderate sarcoplasmic stain-
ing was revealed in the small-diameter fibers, whereas faint
sarcoplasmic and sarcolemmal staining was observed in
the larger-diameter fibers.20 It was previously reported
that the expression of plectin 1f depends on the fiber
type of the muscle, and it was especially localized in type
2A fibers (one of the fast twitch fibers), with moderate
sarcoplasmic staining and rare and weak staining of the
membrane, with the use of plectin-1f-specific antibody.20
In our studies, we showed strong sarcoplasmic staining
but irregular and weak sarcolemmal staining of type 2
fibers, but only rare and faint staining for type 1 fibers in
cross-sections of control skeletal muscle, with the use of
10F6 mAb (Figure 3C). Contrary to the control muscle,
even though there was cytoplasmic staining of type 2
fibers, no sarcolemmal staining of plectin was detected in
the patient muscle (Figure 3D). For this reason, we suggest
that the loss of sarcolemmal staining of plectin in patient’s
muscle might result from the absence of plectin 1f.
To demonstrate the specific ultrastructural features of
the patient muscle, we performed transmission electron838 The American Journal of Human Genetics 87, 834–841, Decembmicroscopy (TEM-Jeol, JEM1400). There was a slight varia-
tion in muscle fiber size, and hypertrophic and atrophic
fibers were observed. An increase in endomysial and
perimysial connective tissue was noted. Internal nuclei
were seen in some fibers. The dilated tubular system from
skeletal muscle of index case was present in some fiber
cross-sections, the sarcolemma displayed duplications
(separation of membranes) (Figures 4A and 4B), and the
presence of an empty space between the sarcolemma and
the contractile elements (sarcomere) was observed (Fig-
ure 4B). The empty spaces generally consisted of swollen
sarcoplasmic reticuli cisternae and glycogen (Figure 4C).
The longitudinal sections revealed focal loss of myofibrillar
organization in some areas (Figures 4D and 4E). The width
of the sarcomere unit was thinner than normal, as well.
Degenerating mitochondria were noted in atrophic fibers,
although the mitochondria number and distribution
revealed an even pattern. Given that plectin 1f is
a sarcolemma-associated protein, a variably enlarged space
between the sarcolemma and the sarcomere might be the
result of plectin 1f deficiency due to the broken anchorage
between these structures. It has been proposed that there is
an interaction between plectin 1f and plectin 1d that is
associated with Z-lines.22 In this situation, a deficiency of
plectin 1f can cause the loss of linkage between plectin 1f
and plectin 1d, which might explain the disorganizationer 10, 2010
Figure 4. Transmission Electron Microscopy
Electron micrographs of the transverse (A–C) and longitudinal (D and E) sections exhibiting the dilated tubular system from skeletal
muscle of patient VI:1.
(A and B) Duplication of the plasmamembrane (separation ofmembranes) is observed (indicated by an asterisk), and the double arrow in
(B) shows the empty space between the sarcolemma and sarcomere.
(C) Black glycogen inclusions (indicatedwithin the circle) and dilated sarcoplasmic reticuli (asterisk) are present in the space between the
sarcolemma and sarcomere.
(D) Mild disalignment of sarcomeres.
(E) Focal variability of Z lines. (N, nucleus; Z, Z lines).
Scale bars represent the following: (A, B, E) 0.5 mm; (C) 0.2 mm; (D) 1 mm.or misalignment of Z-lines. The presence of duplication,
the empty space between the sarcolemma and the contrac-
tile elements, and the focal myofibrillar disorganization
were the striking ultrastructural features in our case, which
were very similar to the findings reported earlier by McMil-
lan et al. in EBS-MD patients with a homozygous plectin-
exon 32 rod domain mutation (p.Arg2465X) in PLEC.23
Although PLEC-associated phenotypes clearly convey
the substantial role of plectin in the heart, skin, and neuro-
muscular junction, potential roles of plectin 1f in these
tissues still remain inconclusive because of a lack of func-
tional data.7–9,24 The absence of any other tissue involve-
ment except skeletal muscle in our patients suggests that
plectin 1f has a major role in muscle.
Tissue-specific expression and isoform-dependent defi-
ciency of plectin explain the muscular dystrophy pheno-
type without skin blistering in our patients. Plectin iso-
forms expressed in skeletal muscle at considerable levels
have different and significant roles in muscle integrity.
Plectin 1d is associated with Z-disks, whereas plectin 1b
colocalizes with mitochondria, which plays a role for
organelle shaping and forms a network between mito-
chondria and the cytoskeleton.20,25 Plectin 1 and 1f are
sarcolemma-associated isoforms and are localized at costa-
meres.20 It has been demonstrated that although exon 1 of
the plectin 1 isoform binds to alpha-dystrobrevin, no inter-
action has been found between plectin 1f and alpha-dys-
trobrevin.26 According to their myoblast-differentiation
experiments, Recniczek et al. found that the temporal
expression profile of plectin 1f is highly similar to dystro-The Americanphin and that there is a direct interaction between plectin
1f and dystrophin and beta-dystroglycan, which is a major
costamere in the muscle.20 They suggested that there is
an association between plectin 1f and the dystrophin-
glycoprotein complex (DGC) via beta-dystroglycan. Plec-
tin 1f binds to dystrophin via its functional actin binding
domain and also binds to beta-dystroglycan by its plakin
domain. The C-terminal part of the protein is an IF-
binding domain that is available for binding to the des-
min, a major intermediate filament in the muscle tissue.
In addition to these proposed models, nothing is known
about proteins specifically binding to the exon 1f part of
the protein. We believe that the unknown LGMD etiology
of a number of families may be associated with the disrup-
tion of these isoforms, in addition to plectin 1f.
In conclusion, we describe a pure LGMD2 that is caused
by a homozygous deletion in exon 1f of PLEC. The overall
clinical phenotype of our patients shows proximal
weighted, generalized muscle weakness without any myas-
thenic features or skin involvement. On the basis of our
index cases, this LGMD2 phenotype manifests in early
childhood and shows very slow progress until the late
teens. However, it may show rapid progression later on;
loss of ambulation in the late 20s has been observed in
one family. Additional cases are needed for confirmation
of our observation. Plectin 1f is one of the particular scaf-
folds for costameric proteins, among other isoforms (plec-
tins 1, 1b, and 1d). Our study emphasizes the importance
of plectin isoforms and their different tasks in the forma-
tion of precise myofiber structure. This study will alsoJournal of Human Genetics 87, 834–841, December 10, 2010 839
shed light on the contribution of tissue- and/or cell-type-
specific expression of gene isoforms for understanding of
the pathologic mechanism of human diseases.Supplemental Data
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